Claim check · Safety, Effectiveness, Study interpretation

Evidence on single peptides versus taking them together

Claim (representative wording, not a quotation): Each of these peptides has evidence behind it, so taking them together must be safe and work.

Plain-English answer

Evidence on each peptide alone is not enough to say what happens when they are used together. The one combination checked here, cagrilintide with semaglutide (CagriSema), was tested in a randomized trial against each component and placebo, and the paper's abstract says its efficacy was unknown beforehand. The results apply to that combination in that trial's population and say nothing about other combinations.

Verdict: Insufficient evidence. The sources WPF read neither support nor contradict the claim. The page states exactly what is missing and where WPF looked.

Scope

Population or organism
Adults without diabetes with overweight or obesity (REDEFINE 1: 3,417 randomized; 68 weeks), plus one east Asian trial (REDEFINE 5: 331 randomized)
Study design
REDEFINE 1: randomized 21:3:3:7 to the combination, semaglutide alone, cagrilintide alone or placebo, plus lifestyle intervention, with effects estimated by the treatment-policy estimand
Boundary
One combination in the trial populations, under trial conditions. It says nothing about any other combination, about use outside a trial, or about dosing. No recommendation is made.

Strongest evidence

What remains uncertain

  • The component-arm figures come from a secondary post hoc analysis of observed on-treatment data for a different outcome (a BMI target), not from the trial's primary analysis. Body-weight change for the component-alone arms was not retrieved: the paper is behind a subscription and the registry posts no results.
  • Both trials were funded by the sponsor of both medicines, and the post hoc analysis includes sponsor employees as authors.
  • A positive result for one combination in one population does not transfer to other combinations, populations or settings, and a combination can add side effects. Combination-versus-component adverse-event comparisons from REDEFINE 1 were not retrieved.
  • REDEFINE 1 and REDEFINE 5 used different estimands, so their weight-change figures are not directly comparable.
  • Regulatory status as of 2026-11-14 (United States): FDA's Novel Drug Approvals pages for 2025 (content current 07/08/2026) and 2026 (content current 11/09/2026) list no cagrilintide or CagriSema product, and an openFDA Drugs@FDA search for cagrilintide returned no match. A company announcement dated 2025-12-18 says an FDA application was filed. FDA does not publish pending applications, so review status cannot be confirmed from an official record. Status in the EU, the UK and elsewhere was not determined from official records.

What would change the answer

  • Registry results or the full REDEFINE 1 paper reporting outcomes and adverse events for each arm, which would let a reader see what the combination added to each component.
  • A randomized trial of any other combination of interest, with component-alone arms and safety reporting, which would support a statement limited to that trial's combination and population.

Exact gaps

  • Body-weight change and adverse events for the semaglutide-alone and cagrilintide-alone arms of REDEFINE 1 were not retrieved.
  • The full texts of REDEFINE 1 and REDEFINE 5 were not read.
  • No regulator outside the United States was checked.

Date checked and review status

Checked: · version 1.6.0

Review status: AI-assisted source verification. Human review: none recorded. Human review is pending and has not happened.

Profiles: /directory/semaglutide

Flagship results: /research/flagship/compare/weight-management

Research journeys: /research/journey/semaglutide

Cite this check

The citation names the version and an address that keeps returning what was checked, even after a newer version is published.

Evidence on single peptides versus taking them together: Evidence on each peptide alone is not enough to say what happens when they are used together. The one combination checked here, cagrilintide with semaglutide (CagriSema), was tested in a randomized trial against each component and placebo, and the paper's abstract says its efficacy was unknown beforehand. The results apply to that combination in that trial's population and say nothing about other combinations. Verdict: Insufficient evidence. Cited from World Peptide Foundation, Peptide Claims & Evidence, version 1.6.0, claim single-peptide-evidence-combined-use, checked 2026-11-14. AI-assisted source verification; human review none recorded.

Page:
https://www.worldpeptidefoundation.org/research/check/single-peptide-evidence-combined-use

Versioned record:
https://www.worldpeptidefoundation.org/api/research/claims/single-peptide-evidence-combined-use?version=1.6.0

Versioned record: /api/research/claims/single-peptide-evidence-combined-use?version=1.6.0